An Open Label, Part-randomised, Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate (FF) When Administered as FF Inhalation Powder From the Novel Dry Powder Inhaler in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Jun 2017
At a glance
- Drugs Fluticasone furoate (Primary) ; Fluticasone furoate (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 21 Aug 2012 New trial record